{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:20:28Z","timestamp":1788477628662,"version":"build-2803163510"},"reference-count":15,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T00:00:00Z","timestamp":1647388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["RETICS RD16\/0008\/0003"],"award-info":[{"award-number":["RETICS RD16\/0008\/0003"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010801","name":"Xunta de Galicia","doi-asserted-by":"publisher","award":["ED431G 2019\/02"],"award-info":[{"award-number":["ED431G 2019\/02"]}],"id":[{"id":"10.13039\/501100010801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministry of Economy, Industry and Competitiveness","doi-asserted-by":"publisher","award":["RTI2018\u2013101840-B-I00"],"award-info":[{"award-number":["RTI2018\u2013101840-B-I00"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["EURONANOMED2019-050-ENAMEP"],"award-info":[{"award-number":["EURONANOMED2019-050-ENAMEP"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>We describe a case of Vogt-Koyanagi-Harada (VKH) disease exacerbation after COVID-19 vaccination. A 46-year-old woman presented with a bilateral granulomatous uveitis 2 days after the first dose of COVID-19 mRNA vaccine (Comirnaty, Pfizer-BioNTech), and was diagnosed with a complete Vogt-Koyanagi-Harada (VKH) disease 4 days after receiving the second dose of the vaccine. Three weeks before the first dose, she had been consulted for blurred vision and mild headaches. The case resolved with high dose intravenous corticosteroids, followed by oral prednisone. The close temporal relationship between the COVID-19 vaccine doses and the worsening of VKH symptoms strongly suggests COVID-19 vaccination as the trigger of its exacerbation.<\/jats:p>","DOI":"10.3390\/cells11061012","type":"journal-article","created":{"date-parts":[[2022,3,16]],"date-time":"2022-03-16T22:09:58Z","timestamp":1647468598000},"page":"1012","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Vogt-Koyanagi-Harada Disease Exacerbation Associated with COVID-19 Vaccine"],"prefix":"10.3390","volume":"11","author":[{"given":"Bego\u00f1a","family":"De Domingo","sequence":"first","affiliation":[{"name":"Service of Ophthalmology, Instituto de Investigaci\u00f3n Sanitaria (IDIS), Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7823-1648","authenticated-orcid":false,"given":"Miguel","family":"L\u00f3pez","sequence":"additional","affiliation":[{"name":"NeurObesity Group, Department of Physiology, CIMUS, Instituto de Investigaci\u00f3n Sanitaria, University of Santiago de Compostela, 15706 Santiago de Compostela, Spain"},{"name":"CIBER Fisiopatolog\u00eda de la Obesidad y Nutrici\u00f3n (CIBERobn), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Lopez-Valladares","sequence":"additional","affiliation":[{"name":"Service of Ophthalmology, Instituto de Investigaci\u00f3n Sanitaria (IDIS), Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esperanza","family":"Ortegon-Aguilar","sequence":"additional","affiliation":[{"name":"Service of Neurology, Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo","family":"Sope\u00f1a-Perez-Arg\u00fcelles","sequence":"additional","affiliation":[{"name":"Service of Internal Medicine, Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Service of Ophthalmology, Instituto de Investigaci\u00f3n Sanitaria (IDIS), Complejo Hospitalario Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain"},{"name":"Ophthalmology and Visual Science, CIMUS, University of Santiago de Compostela, 15705 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/s41577-020-00434-6","article-title":"Immunological considerations for COVID-19 vaccine strategies","volume":"20","author":"Jeyanathan","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1136\/annrheumdis-2021-220289","article-title":"Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"Boyarsky","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/annrheumdis-2021-220231","article-title":"Safety ofthefirstdose ofmRNA SARS-CoV-2vaccines inpatients with rheumatic and musculoskeletal diseases","volume":"80","author":"Connolly","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","volume":"80","author":"Geisen","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"977","DOI":"10.15585\/mmwr.mm7027e2","article-title":"Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices\u2014United States, June 2021","volume":"70","author":"Gargano","year":"2021","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"108665","DOI":"10.1016\/j.clim.2021.108665","article-title":"Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to \u201cpotential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases\u201d","volume":"224","author":"Talotta","year":"2021","journal-title":"Clin. Immunol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Watad, A., De Marco, G., Mahajna, H., Druyan, A., Eltity, M., Hijazi, N., Haddad, A., Elias, M., Zisman, D., and Naffaa, M.E. (2021). Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA\/DNA SARS-CoV-2 Vaccination. Vaccines, 9.","DOI":"10.3390\/vaccines9050435"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0002-9394(01)00925-4","article-title":"Revised diagnostic criteria for Vogt-Koyanagi-Harada disease: Report of an international committee on nomenclature","volume":"131","author":"Read","year":"2001","journal-title":"Am. J. Ophthalmol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.survophthal.2016.05.002","article-title":"Vogt-Koyanagi-Harada disease","volume":"62","author":"Rao","year":"2017","journal-title":"Surv. Ophthalmol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1093\/cid\/ciab465","article-title":"Circulating SARS-CoV-2 Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients","volume":"74","author":"Ogata","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1080\/09273948.2021.1974492","article-title":"Vogt-Koyanagi-Harada Disease Associated with COVID-19 mRNA Vaccine","volume":"29","author":"Koong","year":"2021","journal-title":"Ocul. Immunol. Inflamm."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12348-021-00251-5","article-title":"Reactivation of Vogt-Koyanagi-Harada disease under control for more than 6 years, following anti-SARS-CoV-2 vaccination","volume":"11","author":"Papasavvas","year":"2021","journal-title":"J. Ophthalmic. Inflamm. Infect."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40942-021-00319-3","article-title":"Vogt-Koyanagi-Harada Syndrome following COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccine","volume":"7","author":"Saraceno","year":"2021","journal-title":"Int. J. Retina Vitreous"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102792","DOI":"10.1016\/j.autrev.2021.102792","article-title":"The SARS-CoV-2 as an instrumental trigger of autoimmunity","volume":"20","author":"Dotan","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s40123-021-00338-1","article-title":"Ophthalmological Considerations for COVID-19 Vaccination in Patients with Inflammatory Eye Diseases and Autoimmune Disorders","volume":"10","author":"Chau","year":"2021","journal-title":"Ophthalmol. Ther."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/6\/1012\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:37:48Z","timestamp":1760135868000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/6\/1012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,16]]},"references-count":15,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["cells11061012"],"URL":"https:\/\/doi.org\/10.3390\/cells11061012","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,16]]}}}